vs

Side-by-side financial comparison of Moderna (MRNA) and Primo Brands Corp (PRMB). Click either name above to swap in a different company.

Primo Brands Corp is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.5× Moderna). Primo Brands Corp runs the higher net margin — -0.8% vs -19.7%, a 18.8% gap on every dollar of revenue. Primo Brands Corp produced more free cash flow last quarter ($57.3M vs $-880.0M).

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Primo Brands Corporation is an American-Canadian water company offering multi-gallon bottled water, water dispensers, self-service refill water machines, and water filtration appliances. The company is headquartered in Tampa, Florida, and services residential and commercial customers across the United States, Canada, Europe and Israel.

MRNA vs PRMB — Head-to-Head

Bigger by revenue
PRMB
PRMB
1.5× larger
PRMB
$1.6B
$1.0B
MRNA
Higher net margin
PRMB
PRMB
18.8% more per $
PRMB
-0.8%
-19.7%
MRNA
More free cash flow
PRMB
PRMB
$937.3M more FCF
PRMB
$57.3M
$-880.0M
MRNA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
MRNA
MRNA
PRMB
PRMB
Revenue
$1.0B
$1.6B
Net Profit
$-200.0M
$-13.0M
Gross Margin
79.6%
27.7%
Operating Margin
-25.6%
1.2%
Net Margin
-19.7%
-0.8%
Revenue YoY
-45.4%
Net Profit YoY
-1638.5%
EPS (diluted)
$-0.51
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRNA
MRNA
PRMB
PRMB
Q4 25
$1.6B
Q3 25
$1.0B
$1.8B
Q2 25
$1.7B
Q1 25
$1.6B
Q4 24
$966.0M
Q3 24
$1.9B
$0
Q2 24
$1.3B
Q1 24
$1.1B
Net Profit
MRNA
MRNA
PRMB
PRMB
Q4 25
$-13.0M
Q3 25
$-200.0M
$16.8M
Q2 25
$27.6M
Q1 25
$28.7M
Q4 24
$-1.1B
Q3 24
$13.0M
$-2.0K
Q2 24
$54.5M
Q1 24
$33.5M
Gross Margin
MRNA
MRNA
PRMB
PRMB
Q4 25
27.7%
Q3 25
79.6%
29.9%
Q2 25
31.3%
Q1 25
32.3%
Q4 24
23.5%
Q3 24
72.4%
Q2 24
32.7%
Q1 24
30.4%
Operating Margin
MRNA
MRNA
PRMB
PRMB
Q4 25
1.2%
Q3 25
-25.6%
8.3%
Q2 25
6.5%
Q1 25
9.5%
Q4 24
-129.0%
Q3 24
-3.8%
Q2 24
12.1%
Q1 24
11.0%
Net Margin
MRNA
MRNA
PRMB
PRMB
Q4 25
-0.8%
Q3 25
-19.7%
1.0%
Q2 25
1.6%
Q1 25
1.8%
Q4 24
-115.9%
Q3 24
0.7%
Q2 24
4.1%
Q1 24
2.9%
EPS (diluted)
MRNA
MRNA
PRMB
PRMB
Q4 25
$-0.03
Q3 25
$-0.51
$0.04
Q2 25
$0.07
Q1 25
$0.08
Q4 24
$-2.91
Q3 24
$0.03
$-20.00
Q2 24
$0.25
Q1 24
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRNA
MRNA
PRMB
PRMB
Cash + ST InvestmentsLiquidity on hand
$1.1B
$376.7M
Total DebtLower is stronger
$5.2B
Stockholders' EquityBook value
$9.3B
$3.0B
Total Assets
$12.1B
$10.6B
Debt / EquityLower = less leverage
1.72×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRNA
MRNA
PRMB
PRMB
Q4 25
$376.7M
Q3 25
$1.1B
Q2 25
Q1 25
Q4 24
$1.9B
Q3 24
$1.6B
Q2 24
Q1 24
Total Debt
MRNA
MRNA
PRMB
PRMB
Q4 25
$5.2B
Q3 25
$5.1B
Q2 25
$5.1B
Q1 25
$5.0B
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MRNA
MRNA
PRMB
PRMB
Q4 25
$3.0B
Q3 25
$9.3B
$3.2B
Q2 25
$3.2B
Q1 25
$3.3B
Q4 24
$10.9B
Q3 24
$11.9B
$-2.0K
Q2 24
$-296.8M
Q1 24
$-349.8M
Total Assets
MRNA
MRNA
PRMB
PRMB
Q4 25
$10.6B
Q3 25
$12.1B
$11.0B
Q2 25
$11.0B
Q1 25
$11.0B
Q4 24
$14.1B
Q3 24
$15.8B
$0
Q2 24
Q1 24
Debt / Equity
MRNA
MRNA
PRMB
PRMB
Q4 25
1.72×
Q3 25
1.61×
Q2 25
1.57×
Q1 25
1.51×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRNA
MRNA
PRMB
PRMB
Operating Cash FlowLast quarter
$-847.0M
$203.1M
Free Cash FlowOCF − Capex
$-880.0M
$57.3M
FCF MarginFCF / Revenue
-86.6%
3.7%
Capex IntensityCapex / Revenue
3.2%
9.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.9B
$302.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRNA
MRNA
PRMB
PRMB
Q4 25
$203.1M
Q3 25
$-847.0M
$283.4M
Q2 25
$155.0M
Q1 25
$38.8M
Q4 24
$825.0M
Q3 24
$-1.6B
$0
Q2 24
$102.5M
Q1 24
$6.0M
Free Cash Flow
MRNA
MRNA
PRMB
PRMB
Q4 25
$57.3M
Q3 25
$-880.0M
$167.7M
Q2 25
$101.1M
Q1 25
$-23.2M
Q4 24
$303.0M
Q3 24
$-1.7B
Q2 24
$61.4M
Q1 24
$-17.5M
FCF Margin
MRNA
MRNA
PRMB
PRMB
Q4 25
3.7%
Q3 25
-86.6%
9.5%
Q2 25
5.8%
Q1 25
-1.4%
Q4 24
31.4%
Q3 24
-92.2%
Q2 24
4.7%
Q1 24
-1.5%
Capex Intensity
MRNA
MRNA
PRMB
PRMB
Q4 25
9.4%
Q3 25
3.2%
6.6%
Q2 25
3.1%
Q1 25
3.8%
Q4 24
54.0%
Q3 24
8.1%
Q2 24
3.1%
Q1 24
2.1%
Cash Conversion
MRNA
MRNA
PRMB
PRMB
Q4 25
Q3 25
16.87×
Q2 25
5.62×
Q1 25
1.35×
Q4 24
Q3 24
-120.46×
Q2 24
1.88×
Q1 24
0.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

PRMB
PRMB

Regional Spring Water$765.1M49%
Purified Water$484.5M31%
Other$188.4M12%
Premium Water$90.3M6%
Other Water$25.8M2%

Related Comparisons